Please assess the completion status of the following clinical trial:

Trial Title: Pre-exposure Option for Reducing HIV in the UK.(PROUD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Born to male gender, age 18 years or more~* Previously attended the enrolling clinic on at least one occasion~* Completed a screen for HIV and STIs~* HIV negative by a routinely used assay within 4 weeks prior to or on the day of randomisation~* Reported unprotected anal intercourse (UAI) on more than one occasion within the 90 days prior to randomisation~* Likely, in the opinion of the volunteer, to have UAI in the next 90 days~* Willing and able to comply with the visit schedule throughout the follow-up period~* Willing and able to provide written informed consent~Exclusion Criteria:~* An acute viral illness that could be due to HIV seroconversion~* Any contraindications to Truvada according to the current package insert~* Treatment for hepatitis B infection indicated or ongoing~* Unlikely, in the opinion of the clinician, to comply with the randomised allocation

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Arm A: Immediate offer of Truvada-PrEP (Type: EXPERIMENTAL): Immediate offer of Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)
- Arm B: Deferred (12m) offer of Truvada-PrEP (Type: OTHER): Access to Truvada from 12 months after enrolment

Based on this trial design, predict the completion outcome and termination type (if applicable).